FDA Approves Unknown Drug — PFIZER INC
Pfizer Inc. received FDA approval for BMS-986165 on July 23, 2019, advancing its potential treatment for metabolic diseases. Market analysts anticipate the launch will drive growth in the respiratory and metabolic segments while bolstering Pfizer's pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed